Bristol-Myers Squibb Delivers Solid Fourth Quarter Results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced solid results for the fourth quarter of 2010. This concludes a year in which the Company presented key data on marketed and investigational products across its pipeline, completed important regulatory milestones, continued its focus on strategic transactions and delivered on its commitment to drive shareholder value.
AstraZeneca announced fourth quarter and full year results
- Details
- Category: AstraZeneca
Revenue in the fourth quarter was down 3 percent at CER and declined by 4 percent on an actual basis as a result of the negative impact of exchange rate movements. A strong 5 percent revenue increase in the Rest of World was more than offset by the 12 percent decline in US revenue resulting from generic competition for several products and the absence of H1N1 pandemic influenza vaccine revenue.
Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced financial results for the fourth quarter ended Dec. 31, 2010. Worldwide sales increased 13.4 percent to nearly $10 billion, including an unfavorable 0.4 percent effect of foreign exchange rates.
Pediatric Exclusivity For PLAVIX®
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and sanofi-aventis (EURONEXT: SAN, NYSE: SNY) announced that the United States Food and Drug Administration (FDA) has granted the companies an additional six-month period of exclusivity to market PLAVIX® (clopidogrel bisulfate).
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation. The studies will separately assess the efficacy and safety of two investigational agents, GSK2118436 and GSK1120212,
AstraZeneca Replies to FDA Complete Response Letter for BRILINTA
- Details
- Category: AstraZeneca
AstraZeneca has replied to the US Food and Drug Administration's (FDA) Complete Response Letter (CRL) received for the ticagrelor (BRILINTA) New Drug Application (NDA) on 16 December 2010.
Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme®
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) announced that it will build an additional manufacturing plant in Geel, Belgium, to support the long-term growth of Myozyme® and Lumizyme® for Pompe disease. The company held a ceremony in Geel to mark the start of construction of the new €250 million plant,
More Pharma News ...
- The clinical phase III programme commenced on zicronapine
- Roche personalized investigational medicine shows survival benefit in advanced skin cancer
- Bayer and Regeneron start MYRROR Phase III Trial
- Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility
- GlaxoSmithKline announces Q4 2010 legal charge
- European Commission Clears Acquisition of Genzyme Corporation by sanofi-aventis
- Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance